X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3732) 3732
humans (3561) 3561
vidarabine - analogs & derivatives (3257) 3257
male (2214) 2214
female (2062) 2062
middle aged (1850) 1850
hematology (1688) 1688
vidarabine - administration & dosage (1522) 1522
adult (1480) 1480
vidarabine - therapeutic use (1376) 1376
aged (1375) 1375
oncology (1293) 1293
fludarabine (1154) 1154
antineoplastic combined chemotherapy protocols - therapeutic use (966) 966
leukemia, lymphocytic, chronic, b-cell - drug therapy (942) 942
treatment outcome (848) 848
vidarabine - pharmacology (712) 712
transplantation (692) 692
vidarabine - adverse effects (620) 620
antineoplastic agents - therapeutic use (616) 616
transplantation conditioning - methods (592) 592
cyclophosphamide - administration & dosage (570) 570
animals (553) 553
therapy (546) 546
rituximab (519) 519
adolescent (508) 508
immunology (488) 488
transplantation, homologous (465) 465
chronic lymphocytic-leukemia (434) 434
disease-free survival (430) 430
bone-marrow-transplantation (420) 420
cyclophosphamide (409) 409
abridged index medicus (393) 393
remission induction (392) 392
cancer (387) 387
leukemia (387) 387
chemotherapy (383) 383
aged, 80 and over (361) 361
retrospective studies (356) 356
hematopoietic stem cell transplantation (354) 354
antineoplastic combined chemotherapy protocols - adverse effects (352) 352
survival analysis (347) 347
chronic lymphocytic leukemia (335) 335
recurrence (327) 327
survival rate (325) 325
leukemia, lymphocytic, chronic, b-cell - pathology (324) 324
child (315) 315
hematopoietic stem cell transplantation - methods (311) 311
stem cells (310) 310
antineoplastic combined chemotherapy protocols - administration & dosage (309) 309
stem-cell transplantation (306) 306
care and treatment (300) 300
hematopoietic stem cells (296) 296
prognosis (296) 296
antineoplastic agents - pharmacology (285) 285
follow-up studies (283) 283
versus-host-disease (282) 282
young adult (278) 278
graft vs host disease - prevention & control (274) 274
mice (267) 267
cytarabine - administration & dosage (263) 263
immunosuppressive agents - therapeutic use (258) 258
vidarabine phosphate - analogs & derivatives (258) 258
antineoplastic agents - adverse effects (254) 254
transplantation conditioning (254) 254
apoptosis (250) 250
busulfan - administration & dosage (248) 248
hematology, oncology and palliative medicine (247) 247
acute myeloid-leukemia (238) 238
antineoplastic agents (237) 237
risk factors (236) 236
health aspects (234) 234
time factors (230) 230
research (228) 228
alemtuzumab (225) 225
cyclophosphamide - therapeutic use (223) 223
antineoplastic agents - administration & dosage (220) 220
antibodies, monoclonal - administration & dosage (219) 219
child, preschool (218) 218
survival (217) 217
antimitotic agents (214) 214
combined modality therapy (212) 212
apoptosis - drug effects (211) 211
hematopoietic stem cell transplantation - adverse effects (211) 211
antibodies, monoclonal, murine-derived (203) 203
drug administration schedule (199) 199
cll (196) 196
antibodies, monoclonal - therapeutic use (193) 193
leukemia, myeloid, acute - drug therapy (193) 193
dose-response relationship, drug (190) 190
leukemia, lymphocytic, chronic, b-cell - mortality (189) 189
lymphoma (187) 187
acute myelogenous leukemia (186) 186
non-hodgkins-lymphoma (180) 180
drug resistance, neoplasm (178) 178
whole-body irradiation (176) 176
pharmacology & pharmacy (175) 175
lymphoma, non-hodgkin - drug therapy (170) 170
bone-marrow transplantation (169) 169
dosage and administration (168) 168
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3742) 3742
Chinese (68) 68
Japanese (57) 57
French (31) 31
Spanish (24) 24
German (19) 19
Russian (16) 16
Hungarian (10) 10
Czech (7) 7
Polish (7) 7
Dutch (2) 2
Romanian (2) 2
Danish (1) 1
Finnish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Leukemia Research, ISSN 0145-2126, 2007, Volume 32, Issue 1, pp. 71 - 77
Abstract Triapine® is a potent ribonucleotide reductase (RR) inhibitor that depletes intracellular deoxyribonculeotide pools, especially dATP. We designed a... 
Hematology, Oncology and Palliative Medicine | Rbonucleotide reductase | Fludarabine | Myeloproliferative disorders | Triapine | Refractory acute leukemia | CHRONIC MYELOGENOUS LEUKEMIA | CELLS | RESPONSE CRITERIA | NERVOUS-SYSTEM TOXICITY | HYDROXYUREA | myeloproliferative disorders | rbonucleotide reductase | INTERNATIONAL WORKING GROUP | INDUCTION THERAPY | METABOLISM | ONCOLOGY | refractory acute leukemia | fludarabine | ARA-C | HEMATOLOGY | MYELODYSPLASTIC SYNDROMES | Recurrence | Pyridines - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Treatment Outcome | Myeloproliferative Disorders - drug therapy | Vidarabine - analogs & derivatives | Thiosemicarbazones - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Precursor Cell Lymphoblastic Leukemia-Lymphoma - diet therapy | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Vidarabine - administration & dosage | Myelodysplastic Syndromes - drug therapy | Antimitotic agents | Care and treatment | Oncology, Experimental | Bone marrow | Nucleosides | Clinical trials | Transplantation | Research | Antineoplastic agents | Cancer | Index Medicus | Adenosine | nucleoside analogs | Ribonucleoside-triphosphate reductase | Toxicity | Leukemia | Malignancy | Fever | Metabolic acidosis | Myeloproliferative diseases | triapine | ribonucleotide reductase
Journal Article
Journal Article
Oncotarget, ISSN 1949-2553, 2016, Volume 7, Issue 38, pp. 62091 - 62106
Journal Article
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2014, Volume 20, Issue 11, pp. 1687 - 1695
Journal Article
British Journal of Haematology, ISSN 0007-1048, 01/2009, Volume 144, Issue 1, pp. 41 - 52
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2016, Volume 11, Issue 6, pp. e0157114 - e0157114
Cytotoxic drugs, such as nucleoside analogs and toxins, commonly suffer from off-target effects. One approach to mitigate this problem is to deliver the... 
BREAST-CANCER | TRASTUZUMAB | ANTICANCER | MECHANISM | MULTIDISCIPLINARY SCIENCES | AFFIBODY MOLECULES | LEUKEMIA | MONOCLONAL-ANTIBODIES | PICOMOLAR AFFINITY | PROTEINS | CANCER-THERAPY | Phosphorylation | Cell Proliferation | Receptor, ErbB-2 - genetics | Humans | Ovarian Neoplasms - pathology | Receptor, ErbB-2 - metabolism | Combined Modality Therapy | Vidarabine - analogs & derivatives | Breast Neoplasms - metabolism | Drug Delivery Systems | Breast Neoplasms - therapy | Ovarian Neoplasms - genetics | Vidarabine - pharmacology | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Ovarian Neoplasms - therapy | Female | Ovarian Neoplasms - metabolism | Deoxycytidine Kinase - genetics | Tumor Cells, Cultured | Apoptosis | Antimitotic agents | Complications and side effects | Drug targeting | Dosage and administration | Research | Antineoplastic agents | Nucleoside analogs | Cell proliferation | Drugs | Flow cytometry | Biotechnology | Drug delivery systems | Leukemia | Clinical trials | Cytotoxicity | Activation | Biochemistry | Kinases | Tissues | Cancer therapies | Cell surface | Analogs | Proteins | Deoxycytidine kinase | Cell cycle | Cell division | Breast cancer | Tumor cell lines | ErbB-2 protein | Cytometry | Fludarabine | Internalization | Reagents | Cell lines | Nucleosides | Toxins | Ankyrin | Binding sites | Cancer | Tumors | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 02/2001, Volume 97, Issue 3, pp. 631 - 637
Journal Article
Blood, ISSN 0006-4971, 11/2000, Volume 96, Issue 10, pp. 3537 - 3543
Journal Article
Journal of Proteome Research, ISSN 1535-3893, 03/2011, Volume 10, Issue 3, pp. 1030 - 1042
Journal Article